collection
https://read.qxmd.com/read/34635910/ecco-guidelines-on-therapeutics-in-ulcerative-colitis-surgical-treatment
#1
JOURNAL ARTICLE
Antonino Spinelli, Stefanos Bonovas, Johan Burisch, Torsten Kucharzik, Michel Adamina, Vito Annese, Oliver Bachmann, Dominik Bettenworth, Maria Chaparro, Wladyslawa Czuber-Dochan, Piotr Eder, Pierre Ellul, Catarina Fidalgo, Gionata Fiorino, Paolo Gionchetti, Javier P Gisbert, Hannah Gordon, Charlotte Hedin, Stefan Holubar, Marietta Iacucci, Konstantinos Karmiris, Konstantinos Katsanos, Uri Kopylov, Peter L Lakatos, Theodore Lytras, Ivan Lyutakov, Nurulamin Noor, Gianluca Pellino, Daniele Piovani, Edoardo Savarino, Francesco Selvaggi, Bram Verstockt, Glen Doherty, Tim Raine, Yves Panis
This is the second of a series of two articles reporting the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the management of adult patients with ulcerative colitis [UC]. The first article is focused on medical management, and the present article addresses medical treatment of acute severe ulcerative colitis [ASUC] and surgical management of medically refractory UC patients, including preoperative optimisation, surgical strategies, and technical issues. The article provides advice for a variety of common clinical and surgical conditions...
February 23, 2022: Journal of Crohn's & Colitis
https://read.qxmd.com/read/34626832/coffee-consumption-is-associated-with-lower-liver-stiffness-a-nationally-representative-study
#2
JOURNAL ARTICLE
Sebastian Niezen, Manaav Mehta, Z Gordon Jiang, Elliot B Tapper
BACKGROUND & AIMS: Coffee is associated with a reduced risk of liver disease. This association is limited by important sources of confounding such as recall bias, healthy user bias, and indirect measures of liver outcomes or health. We aimed to examine the impact of coffee consumption with liver fibrosis and steatosis in a nationally representative sample. METHODS: We evaluated 4510 subjects 20 years and older from the 2017 to 2018 National Health and Nutrition Examination Survey study who underwent both transient elastography and two 24-hour dietary recall examinations...
September 2022: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/34579936/aga-clinical-practice-guideline-on-the-management-of-coagulation-disorders-in-patients-with-cirrhosis
#3
JOURNAL ARTICLE
Robert S O'Shea, Perica Davitkov, Cynthia W Ko, Anita Rajasekhar, Grace L Su, Shahnaz Sultan, Alina M Allen, Yngve Falck-Ytter
No abstract text is available yet for this article.
November 2021: Gastroenterology
https://read.qxmd.com/read/34543257/comparison-of-cap-assisted-vs-conventional-endoscopic-technique-for-management-of-food-bolus-impaction-in-the-esophagus-results-of-a-multicenter-randomized-controlled-trial
#4
MULTICENTER STUDY
Marie Ooi, Tuan Duong, Richard Holman, Dep Huynh, Abdulnasser Lafta, Florian Grimpen, Mark Appleyard, Chris K Rayner, Nam Q Nguyen
INTRODUCTION: "Push" or "pull" techniques with the use of snares, forceps, baskets, and grasping devices are conventionally used to manage esophageal food bolus impaction (FBI). A novel cap-assisted technique has recently been advocated to reduce time taken for food bolus (FB) removal. This study aimed to compare the effectiveness of the cap-assisted technique against conventional methods of esophageal FB removal in a randomized controlled trial. METHODS: Consecutive patients with esophageal FBI requiring endoscopic removal, from 3 Australian tertiary hospitals between 2017 and 2019, were randomized to either the cap-assisted technique or the conventional technique...
November 1, 2021: American Journal of Gastroenterology
https://read.qxmd.com/read/34331913/a-clinical-approach-to-chronic-diarrhea
#5
JOURNAL ARTICLE
Barbara Dutra, Shaheer Siddiqui, Jamie Everett
No abstract text is available yet for this article.
March 2022: Gastroenterology
https://read.qxmd.com/read/34160593/ecco-topical-review-refractory-inflammatory-bowel-disease
#6
JOURNAL ARTICLE
Tim Raine, Bram Verstockt, Uri Kopylov, Konstantinos Karmiris, Rimma Goldberg, Raja Atreya, Johan Burisch, John Burke, Pierre Ellul, Charlotte Hedin, Stefan D Holubar, Konstantinos Katsanos, Triana Lobaton, Carsten Schmidt, Garret Cullen
Inflammatory bowel disease is a chronic disease with variable degrees of extent, severity, and activity. A proportion of patients will have disease that is refractory to licensed therapies, resulting in significant impairment in quality of life. The treatment of these patients involves a systematic approach by the entire multidisciplinary team, with particular consideration given to medical options including unlicensed therapies, surgical interventions, and dietetic and psychological support. The purpose of this review is to guide clinicians through this process and provide an accurate summary of the available evidence for different strategies...
October 7, 2021: Journal of Crohn's & Colitis
https://read.qxmd.com/read/34182150/long-term-treatment-of-eosinophilic-esophagitis-with-budesonide-oral-suspension
#7
RANDOMIZED CONTROLLED TRIAL
Evan S Dellon, Margaret H Collins, David A Katzka, Vincent A Mukkada, Gary W Falk, Robin Morey, Bridgett Goodwin, Jessica D Eisner, Lan Lan, Nirav K Desai, James Williams, Ikuo Hirano
BACKGROUND & AIMS: We evaluated treatment withdrawal, long-term outcomes, and safety of budesonide oral suspension (BOS) 2.0 mg twice daily in patients with eosinophilic esophagitis who completed a 12-week induction study. METHODS: Induction full responders (≤6 eosinophils per high-power field [eos/hpf] and ≥30% reduction in the Dysphagia Symptom Questionnaire score) to BOS 2.0 mg twice daily (ORBIT1/SHP621-301/NCT02605837) were randomized to continue BOS (BOS-BOS) or withdraw to placebo (BOS-PBO) for 36 weeks (ORBIT2/SHP621-302/NCT02736409)...
July 2022: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/34048936/tofacitinib-for-biologic-experienced-hospitalized-patients-with-acute-severe-ulcerative-colitis-a-retrospective-case-control-study
#8
JOURNAL ARTICLE
Jeffrey A Berinstein, Jessica L Sheehan, Michael Dias, Elliot M Berinstein, Calen A Steiner, Laura A Johnson, Randolph E Regal, John I Allen, Kelly C Cushing, Ryan W Stidham, Shrinivas Bishu, Jami A R Kinnucan, Shirley A Cohen-Mekelburg, Akbar K Waljee, Peter D R Higgins
BACKGROUND & AIMS: Despite rescue therapy, more than 30% of patients with acute severe ulcerative colitis (ASUC) require colectomy. Tofacitinib is a rapidly acting Janus kinase inhibitor with proven efficacy in ulcerative colitis. Tofacitinib may provide additional means for preventing colectomy in patients with ASUC. METHODS: A retrospective case-control study was performed evaluating the efficacy of tofacitinib induction in biologic-experienced patients admitted with ASUC requiring intravenous corticosteroids...
October 2021: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/33940007/approach-to-the-management-of-recently-diagnosed-inflammatory-bowel-disease-patients-a-user-s-guide-for-adult-and-pediatric-gastroenterologists
#9
REVIEW
Manasi Agrawal, Elizabeth A Spencer, Jean-Frederic Colombel, Ryan C Ungaro
Inflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are chronic, progressive, immune-mediated diseases of adults and children that have no cure. IBD can cause significant morbidity and lead to complications such as strictures, fistulas, infections, and cancer. In children, IBD can also result in growth impairment and pubertal delays. IBD is highly heterogenous, with severity ranging from mild to severe and symptoms ranging from mild to debilitating. Delay in IBD diagnosis, especially in Crohn's disease, is common and associated with adverse outcomes...
July 2021: Gastroenterology
https://read.qxmd.com/read/33838348/comparative-efficacy-and-rapidity-of-action-for-infliximab-vs-ustekinumab-in-biologic-na%C3%A3-ve-crohn-s-disease
#10
RANDOMIZED CONTROLLED TRIAL
Neeraj Narula, Emily C L Wong, Parambir S Dulai, Neil K Sengupta, John K Marshall, Jean-Frederic Colombel, Walter Reinisch
BACKGROUND & AIMS: Comparative effectiveness has become increasingly important to help position therapies for inflammatory bowel disease. We compared the efficacy and rapidity of onset of action of infliximab vs ustekinumab induction therapy for moderate to severe biologic-naïve Crohn's disease (CD) using patient-level data from randomized controlled trials. METHODS: This was a post hoc analysis of 2 large CD clinical trial programs that included data on 420 biologic-naïve CD patients...
July 2022: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/33878471/association-of-adenoma-detection-rate-and-adenoma-characteristics-with-colorectal-cancer-mortality-after-screening-colonoscopy
#11
JOURNAL ARTICLE
Elisabeth Waldmann, Andreas A Kammerlander, Irina Gessl, Daniela Penz, Barbara Majcher, Anna Hinterberger, Michael Bretthauer, Michael H Trauner, Monika Ferlitsch
BACKGROUND & AIMS: The adenoma detection rate (ADR) and characteristics of previously resected adenomas are associated with colorectal cancer (CRC) incidence and mortality. However, the combined effect of both factors on CRC mortality is unknown. PATIENTS AND METHODS: Using data of the Austrian quality assurance program for screening colonoscopy, we evaluated the combined effect of ADR and lesion characteristics on subsequent risk for CRC mortality. We analyzed mortality rates for individuals with low-risk adenomas (1-2 adenomas <10 mm), individuals with high-risk adenomas (advanced adenomas or ≥3 adenomas), and after negative colonoscopy (negative colonoscopy or small hyperplastic polyps) performed by endoscopists with an ADR <25% compared with ≥25%...
September 2021: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/33813072/aga-clinical-practice-update-on-the-optimal-management-of-the-malignant-alimentary-tract-obstruction-expert-review
#12
REVIEW
Osman Ahmed, Jeffrey H Lee, Christopher C Thompson, Ashley Faulx
BACKGROUND & AIMS: The purpose of this expert review is to describe the current methodologies available to manage malignant alimentary tract obstructions as well the evidence behind the various methods (including their efficacy and safety), indications, and appropriate timing of interventions. METHODS: This is not a formal systematic review but is based on a review of the literature to provide best practice advice statements. No formal rating of the quality of evidence or strength of recommendation is carried out...
September 2021: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/33819666/advances-in-the-comprehensive-management-of-postoperative-crohn-s-disease
#13
REVIEW
Robert Battat, William J Sandborn
Patients with postoperative Crohn's disease are difficult to manage because of their risk of experiencing a more severe course, multiple symptom confounders, and poor sensitivity of symptomatic remission to rule out intestinal inflammation. In this group, data are lacking on biologic therapeutic efficacy, and recommendations are lacking for those with multiple medication failures. Novel noninvasive testing can simultaneously exclude alternate causes of symptoms (serum C4, fecal fat, small intestinal bowel overgrowth breath testing) and assess intestinal inflammation (fecal calprotectin, endoscopic healing index)...
July 2022: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/33741500/aga-clinical-practice-update-on-evaluation-and-management-of-early-complications-after-bariatric-metabolic-surgery-expert-review
#14
JOURNAL ARTICLE
Vivek Kumbhari, David E Cummings, Anthony N Kalloo, Philip R Schauer
DESCRIPTION: Endoscopic techniques are paramount in the identification and management of complications after surgery, though collaboration with other specialties is obligatory. Unfortunately, the evaluation and treatment algorithms are not standardized and there is a paucity of high-quality prospective studies to provide clarity regarding the best approach. The purpose of this clinical practice update is to apprise the clinician with respect to the endoscopic evaluation and management of patients with early (<90 days) complications after undergoing bariatric/metabolic surgery...
August 2021: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/33657293/a-randomized-trial-of-albumin-infusions-in-hospitalized-patients-with-cirrhosis
#15
RANDOMIZED CONTROLLED TRIAL
Louise China, Nick Freemantle, Ewan Forrest, Yiannis Kallis, Stephen D Ryder, Gavin Wright, Andrew J Portal, Natalia Becares Salles, Derek W Gilroy, Alastair O'Brien
BACKGROUND: Infection and increased systemic inflammation cause organ dysfunction and death in patients with decompensated cirrhosis. Preclinical studies provide support for an antiinflammatory role of albumin, but confirmatory large-scale clinical trials are lacking. Whether targeting a serum albumin level of 30 g per liter or greater in these patients with repeated daily infusions of 20% human albumin solution, as compared with standard care, would reduce the incidences of infection, kidney dysfunction, and death is unknown...
March 4, 2021: New England Journal of Medicine
https://read.qxmd.com/read/33657038/acg-clinical-guidelines-colorectal-cancer-screening-2021
#16
JOURNAL ARTICLE
Aasma Shaukat, Charles J Kahi, Carol A Burke, Linda Rabeneck, Bryan G Sauer, Douglas K Rex
Colorectal cancer (CRC) is the third most common cancer in men and women in the United States. CRC screening efforts are directed toward removal of adenomas and sessile serrated lesions and detection of early-stage CRC. The purpose of this article is to update the 2009 American College of Gastroenterology CRC screening guidelines. The guideline is framed around several key questions. We conducted a comprehensive literature search to include studies through October 2020. The inclusion criteria were studies of any design with men and women age 40 years and older...
March 1, 2021: American Journal of Gastroenterology
https://read.qxmd.com/read/33619914/european-guidelines-on-microscopic-colitis-united-european-gastroenterology-and-european-microscopic-colitis-group-statements-and-recommendations
#17
JOURNAL ARTICLE
Stephan Miehlke, Danila Guagnozzi, Yamile Zabana, Gian E Tontini, Anne-Marie Kanstrup Fiehn, Signe Wildt, Johan Bohr, Ole Bonderup, Gerd Bouma, Mauro D'Amato, Peter J Heiberg Engel, Fernando Fernandez-Banares, Gilles Macaigne, Henrik Hjortswang, Elisabeth Hultgren-Hörnquist, Anastasios Koulaouzidis, Jouzas Kupcinskas, Stefania Landolfi, Giovanni Latella, Alfredo Lucendo, Ivan Lyutakov, Ahmed Madisch, Fernando Magro, Wojciech Marlicz, Emese Mihaly, Lars K Munck, Ann-Elisabeth Ostvik, Árpád V Patai, Plamen Penchev, Karolina Skonieczna-Żydecka, Bas Verhaegh, Andreas Münch
INTRODUCTION: Microscopic colitis is a chronic inflammatory bowel disease characterised by normal or almost normal endoscopic appearance of the colon, chronic watery, nonbloody diarrhoea and distinct histological abnormalities, which identify three histological subtypes, the collagenous colitis, the lymphocytic colitis and the incomplete microscopic colitis. With ongoing uncertainties and new developments in the clinical management of microscopic colitis, there is a need for evidence-based guidelines to improve the medical care of patients suffering from this disorder...
February 22, 2021: United European Gastroenterology Journal
https://read.qxmd.com/read/33618027/adenoma-detection-rate-adr-irrespective-of-indication-is-comparable-to-screening-adr-implications-for-quality-monitoring
#18
JOURNAL ARTICLE
Tonya Kaltenbach, Andrew Gawron, Craig S Meyer, Samir Gupta, Amandeep Shergill, Jason A Dominitz, Roy M Soetikno, Tiffany Nguyen-Vu, Mary A Whooley, Charles J Kahi
BACKGROUND & AIMS: Adenoma detection rate (ADR) is a key measure of colonoscopy quality. However, efficient measurement of ADR can be challenging because many colonoscopies are performed for non-screening purposes. Measuring ADR without being restricted to screening indication may likely facilitate more widespread implementation of quality monitoring. We hypothesized that the ADR for all colonoscopies, irrespective of the indication, would be equivalent to the ADR for screening colonoscopies...
September 2021: Clinical Gastroenterology and Hepatology
https://read.qxmd.com/read/33630766/anticoagulation-and-transjugular-intrahepatic-portosystemic-shunt-for-the-management-of-portal-vein-thrombosis-in-cirrhosis-a-prospective-observational-study
#19
JOURNAL ARTICLE
Yong Lv, Wei Bai, Kai Li, Zhengyu Wang, Wengang Guo, Bohan Luo, Jianhong Wang, Qiuhe Wang, Enxin Wang, Dongdong Xia, Xiaomei Li, Jie Yuan, Na Han, Jing Niu, Zhanxin Yin, Daiming Fan, Guohong Han
INTRODUCTION: Current guidelines recommend anticoagulation as the mainstay of portal vein thrombosis (PVT) treatment in cirrhosis. However, because of the heterogeneity of PVT, anticoagulation alone does not always achieve satisfactory results. This study aimed to prospectively evaluate an individualized management algorithm using a wait-and-see strategy (i.e., no treatment), anticoagulation, and transjugular intrahepatic portosystemic shunt (TIPS) to treat PVT in cirrhosis. METHODS: Between February 2014 and June 2018, 396 consecutive patients with cirrhosis with nonmalignant PVT were prospectively included in a tertiary care center, of which 48 patients (12...
July 1, 2021: American Journal of Gastroenterology
https://read.qxmd.com/read/33631137/scoping-out-a-better-parental-leave-policy-for-gastroenterology-fellows
#20
JOURNAL ARTICLE
Kara Wegermann
No abstract text is available yet for this article.
February 22, 2021: Clinical Gastroenterology and Hepatology
label_collection
label_collection
4416
1
2
2021-03-02 03:07:33
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.